Immunotherapy for Epstein-Barr virus-associated malignancies.
Drug News Perspect
; 23(4): 221-8, 2010 May.
Article
em En
| MEDLINE
| ID: mdl-20520851
ABSTRACT
Epstein-Barr virus (EBV) is present in the malignant cells of several human cancers including post-transplant lymphoproliferative disease (PTLD), Hodgkin's lymphoma, nasopharyngeal carcinoma, natural killer/T lymphomas and Burkitt's lymphoma. Yet in > 90% of the world's adult population, who carry EBV as a lifelong asymptomatic infection, the oncogenic potential of this virus is controlled by a strong virus-specific T-cell response. Accordingly, EBV-associated malignancies represent good candidates for a T-cell-based therapy and provide an important model for developing such therapies for other human cancers. This review summarizes the impressive results seen with T-cell therapy for PTLD and discusses, in the light of recent technological advances, the prospects for developing more effective approaches for other EBV-associated cancers.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Linfócitos T Citotóxicos
/
Transplante de Órgãos
/
Transplante de Células-Tronco Hematopoéticas
/
Infecções por Vírus Epstein-Barr
/
Imunoterapia
/
Transtornos Linfoproliferativos
/
Neoplasias
Tipo de estudo:
Prognostic_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
Drug News Perspect
Ano de publicação:
2010
Tipo de documento:
Article